Rezolute Future Growth

Future criteria checks 2/6

Rezolute is forecast to grow earnings and revenue by 52.4% and 69.2% per annum respectively while EPS is expected to grow by 53.5% per annum.

Key information

52.4%

Earnings growth rate

53.5%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	69.2%
Future return on equity	n/a
Analyst coverage	Good
Last updated	12 Nov 2024

Recent future growth updates

Recent updates

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

May 22

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Feb 13

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 21

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12

Earnings and Revenue Growth Forecasts

NasdaqCM:RZLT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2027	48	-73	-39	-102	7
6/30/2026	5	-88	-65	-77	10
6/30/2025	N/A	-69	-79	-90	10
9/30/2024	N/A	-69	-63	-63	N/A
6/30/2024	N/A	-68	-57	-57	N/A
3/31/2024	N/A	-58	-50	-50	N/A
12/31/2023	N/A	-57	-53	-53	N/A
9/30/2023	N/A	-56	-48	-47	N/A
6/30/2023	N/A	-52	-45	-44	N/A
3/31/2023	N/A	-48	-45	-45	N/A
12/31/2022	N/A	-44	-41	-41	N/A
9/30/2022	N/A	-43	-41	-41	N/A
6/30/2022	N/A	-41	-40	-40	N/A
3/31/2022	N/A	-38	-33	-33	N/A
12/31/2021	N/A	-31	-24	-24	N/A
9/30/2021	N/A	-25	-23	-23	N/A
6/30/2021	N/A	-21	-20	-20	N/A
3/31/2021	N/A	-18	-19	-19	N/A
12/31/2020	N/A	-19	-20	-20	N/A
9/30/2020	N/A	-19	-19	-19	N/A
6/30/2020	N/A	-20	-24	-24	N/A
3/31/2020	N/A	-20	-24	-24	N/A
12/31/2019	N/A	-37	-27	-27	N/A
9/30/2019	N/A	-34	-23	-23	N/A
6/30/2019	N/A	-33	-15	-15	N/A
3/31/2019	N/A	-42	-15	-15	N/A
12/31/2018	N/A	-25	-9	-9	N/A
9/30/2018	N/A	-27	-11	-11	N/A
6/30/2018	N/A	-30	N/A	-14	N/A
3/31/2018	N/A	-24	N/A	-14	N/A
12/31/2017	N/A	-27	N/A	-15	N/A
9/30/2017	N/A	-27	N/A	-15	N/A
6/30/2017	N/A	-24	N/A	-13	N/A
3/31/2017	N/A	-27	N/A	-13	N/A
12/31/2016	N/A	-22	N/A	-12	N/A
9/30/2016	N/A	-21	N/A	-11	N/A
6/30/2016	N/A	-21	N/A	-10	N/A
3/31/2016	N/A	-14	N/A	-9	N/A
12/31/2015	N/A	-14	N/A	-9	N/A
9/30/2015	N/A	-12	N/A	-8	N/A
6/30/2015	N/A	-11	N/A	-7	N/A
3/31/2015	N/A	-10	N/A	-7	N/A
12/31/2014	N/A	-12	N/A	-6	N/A
9/30/2014	N/A	-11	N/A	-5	N/A
6/30/2014	N/A	-10	N/A	-3	N/A
3/31/2014	N/A	-9	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RZLT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RZLT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RZLT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RZLT's revenue (69.2% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: RZLT's revenue (69.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RZLT's Return on Equity is forecast to be high in 3 years time

Rezolute Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 7.5% to US$12.78

Price target increased by 7.2% to US$12.75

Consensus EPS estimates upgraded to US$0.98 loss

Price target increased by 8.1% to US$11.89

Price target increased by 9.4% to US$10.57

Price target increased by 9.0% to US$8.50

Recent updates

Price target increased by 7.5% to US$12.78

Rezolute, Inc., Annual General Meeting, Dec 05, 2024

Price target increased by 7.2% to US$12.75

Consensus EPS estimates upgraded to US$0.98 loss

Insufficient new directors

Price target increased by 8.1% to US$11.89

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

New major risk - Revenue and earnings growth

Price target decreased by 30% to US$7.80

Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Price target decreased by 7.9% to US$11.60

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema

High number of new and inexperienced directors

Price target decreased to US$12.60

Rezolute GAAP EPS of -$0.37

Rezolute, Inc. Promotes Brian Roberts to Chief Medical Officer

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased to US$19.20

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $117.587085 million.

Rezolute, Inc. Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Rezolute, Inc., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Rezolute, Inc Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Rezolute, Inc. Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies At ESPE 2021

Rezolute, Inc. Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

Rezolute, Inc. Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

Price target decreased to US$26.50

High number of new and inexperienced directors

Price target decreased to US$27.00

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute, Inc. Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

Rezolute shares rise on positive topline results from RZ402 eye disease trial

Rezolute, Inc. Announces Board Appointments

New 90-day low: US$11.98

Rezolute, Inc. Announces Phase 2B Study of RZ358 Continues to Enroll Congenital Hyperinsulinism (HI) Patients Worldwide

Rezolute Announces Initiation of Phase 1 Study of RZ402 for the Treatment of Diabetic Macular Edema

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

New 90-day low: US$12.94

Rezolute, Inc. Announces Resignation of Jung-Hee Lim as a Member of the Board of Directors, Audit Committee and Compensation Committee

Price target raised to US$31.50

Rezolute, Inc. Announces CFO Changes

Rezolute, Inc. announced that it expects to receive $40.92 million in funding from BVF Partners LP, Citadel Advisors LLC, and other investors

Rezolute, Inc. announced delayed annual 10-K filing

Rezolute Announces Publication of Rz402 Data in Diabetic Macular Edema (Dme) in Investigative Ophthalmology & Visual Science